Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.
Cuffe S, Bourredjem A, Graziano S, Pignon JP, Domerg C, Ezzalfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Jänne PA, Tsao MS, Shepherd FA. Cuffe S, et al. Among authors: capelletti m. J Thorac Oncol. 2012 Jun;7(6):963-72. doi: 10.1097/JTO.0b013e31824fe9e6. J Thorac Oncol. 2012. PMID: 22588152 Free PMC article. Clinical Trial.
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
Shepherd FA, Domerg C, Hainaut P, Jänne PA, Pignon JP, Graziano S, Douillard JY, Brambilla E, Le Chevalier T, Seymour L, Bourredjem A, Le Teuff G, Pirker R, Filipits M, Rosell R, Kratzke R, Bandarchi B, Ma X, Capelletti M, Soria JC, Tsao MS. Shepherd FA, et al. Among authors: capelletti m. J Clin Oncol. 2013 Jun 10;31(17):2173-81. doi: 10.1200/JCO.2012.48.1390. Epub 2013 Apr 29. J Clin Oncol. 2013. PMID: 23630215 Free PMC article. Clinical Trial.
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach S, Fontes C, Shi Y, Chalasani P, Jänne PA. Redig AJ, et al. Among authors: capelletti m. Clin Cancer Res. 2016 Jul 1;22(13):3148-56. doi: 10.1158/1078-0432.CCR-15-2377. Epub 2016 Feb 9. Clin Cancer Res. 2016. PMID: 26861459 Free PMC article.
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.
Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA. Bahcall M, et al. Among authors: capelletti m. Clin Cancer Res. 2018 Dec 1;24(23):5963-5976. doi: 10.1158/1078-0432.CCR-18-0876. Epub 2018 Aug 2. Clin Cancer Res. 2018. PMID: 30072474 Free PMC article.
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA. Jänne PA, et al. Among authors: capelletti m. J Clin Oncol. 2012 Jun 10;30(17):2063-9. doi: 10.1200/JCO.2011.40.1315. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547605 Free PMC article. Clinical Trial.
Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
Ogino A, Choi J, Lin M, Wilkens MK, Calles A, Xu M, Adeni AE, Chambers ES, Capelletti M, Butaney M, Gray NS, Gokhale PC, Palakurthi S, Kirschmeier P, Oxnard GR, Sholl LM, Jänne PA. Ogino A, et al. Among authors: capelletti m. Mol Oncol. 2021 Jan;15(1):27-42. doi: 10.1002/1878-0261.12673. Epub 2020 Nov 25. Mol Oncol. 2021. PMID: 32191822 Free PMC article.
Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, Stephens PJ, Miller VA, Lindeman NI, Munir KJ, Richards WG, Jänne PA. Capelletti M, et al. Clin Cancer Res. 2014 Dec 15;20(24):6551-8. doi: 10.1158/1078-0432.CCR-14-1337. Epub 2014 Oct 7. Clin Cancer Res. 2014. PMID: 25294908
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Tiseo M, Capelletti M, De Palma G, Franciosi V, Cavazzoni A, Mozzoni P, Alfieri RR, Goldoni M, Galetti M, Bortesi B, Bozzetti C, Loprevite M, Boni L, Camisa R, Rindi G, Petronini PG, Ardizzoni A. Tiseo M, et al. Among authors: capelletti m. J Thorac Oncol. 2008 Oct;3(10):1104-11. doi: 10.1097/JTO.0b013e3181861d67. J Thorac Oncol. 2008. PMID: 18827605 Free article.
69 results